Aclaris Therapeutics (ACRS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Aclaris Therapeutics (ACRS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $667M, trading at $5.54 on the NASDAQ. This SniperIQ fundamentals page covers Aclaris Therapeutics's valuation, profitability (net margin -832.6%), revenue ($8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aclaris Therapeutics's market cap?
Aclaris Therapeutics (ACRS) has a market capitalization of approximately $667M, trading at $5.54 on the NASDAQ. Market cap moves with the live share price.
What is Aclaris Therapeutics's P/E ratio?
Aclaris Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aclaris Therapeutics?
Aclaris Therapeutics runs a net profit margin of -832.6%, a gross margin of 76.3%, and an operating margin of -961.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aclaris Therapeutics generate?
Aclaris Therapeutics reported revenue of $8M for fiscal year 2025, with net income of -$65M and earnings per share (EPS) of -0.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aclaris Therapeutics pay a dividend?
Aclaris Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Aclaris Therapeutics financially healthy?
Aclaris Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 4.03x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aclaris Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aclaris Therapeutics (ACRS) the key facts are: market cap $667M, revenue $8M, 52-week range 1.46-5.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aclaris Therapeutics's full fundamentals live
Get Aclaris Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.